<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FULVESTRANT</span><br/>(ful-ves'trant)<br/><span class="topboxtradename">Faslodex<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">hormone and synthetic substitute</span>; <span class="classification">antiestrogen</span><br/><b>Prototype: </b>Tamoxifen citrate<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg/mL in 2.5 mL, 5 mL syringes</p>
<h1><a name="action">Actions</a></h1>
<p>Fulvestrant is an estrogen receptor antagonist that selectively binds to the estrogen receptors (ER) of breast cancer cells.
         It competes well with estradiol (estrogen) in binding to the estrogen receptor sites. Estrogen stimulates the tumor growth
         of estrogen-sensitive breast tissue cancer cells in postmenopausal women.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In postmenopausal women, many breast cancers have estrogen receptors (ERs), and the growth of these tumors is stimulated by
         estrogen. Therefore, fulvestrant decreases estrogen-sensitive breast tissue tumor growth.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following
         antiestrogen therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fulvestrant; pregnancy (category D); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate to severe liver impairment; safety and effectiveness in children not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 250 mg once/mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Do not administer unless the possibility of pregnancy has been ruled out.</li>
<li>Break the seal of the white plastic cover on the syringe luer connector to remove the cover with the attached rubber tip cap.
            Twist to lock the needle to the luer connector. Remove excess gas from the syringe (a small gas bubble may remain).
         </li>
<li>Administer slowly in the buttock.</li>
<li>Immediately activate needle protection device upon withdrawal from patient by pushing lever arm completely forward until needle
            tip is fully covered.
         </li>
<li>Store in a refrigerator, 2°8° C (36°46° F) in original container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Asthenia, pain, injection site pain,</span> flu-like syndrome, fever, peripheral edema. <span class="typehead">CNS:</span> Dizziness, insomnia, paresthesia, depression, anxiety. <span class="typehead">CV:</span>
<span class="speceff-common">Vasodilation.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, constipation, diarrhea,</span> anorexia. <span class="typehead"> Hematologic:</span>  Anemia. <span class="typehead">Musculoskeletal:</span>
<span class="speceff-common">Bone pain,</span> arthritis. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Pharyngitis, dyspnea, cough.</span>
<span class="typehead">Skin:</span> Rash, sweating. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions reported. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 7 d. <span class="typehead">Duration:</span> 1 mo. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Metabolized via multiple pathways in liver. <span class="typehead">Elimination:</span> Primarily excreted in bile. <span class="typehead">Half-Life:</span> 40 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of tumor progression.</li>
<li>Lab tests: Monitor periodic CBC with differential.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use two methods of contraception while taking this drug. Immediately notify physician if you think you are pregnant.</li>
<li>Report vaginal bleeding to physician. Understand the possibility of drug-induced menstrual irregularities before starting
            treatment.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>